Tsveta Milanova Sells 2,804 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Agios Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ:AGIO opened at $35.90 on Thursday. The company has a market cap of $2.05 billion, a price-to-earnings ratio of 3.16 and a beta of 0.87. The business has a 50 day moving average price of $46.94 and a 200 day moving average price of $45.56. Agios Pharmaceuticals, Inc. has a twelve month low of $20.96 and a twelve month high of $62.58.

Analysts Set New Price Targets

Several brokerages have recently commented on AGIO. Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Hold” and an average price target of $56.33.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp raised its stake in Agios Pharmaceuticals by 13.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company’s stock valued at $9,622,000 after purchasing an additional 27,193 shares during the last quarter. TD Asset Management Inc raised its position in shares of Agios Pharmaceuticals by 34.6% during the second quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company’s stock valued at $9,076,000 after buying an additional 54,054 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the second quarter valued at about $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the second quarter worth about $40,000. Finally, Headlands Technologies LLC bought a new position in Agios Pharmaceuticals during the second quarter valued at about $494,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.